Several other research firms have also commented on SNY. Zacks Investment Research lowered Sanofi from a hold rating to a sell rating in a research note on Wednesday, February 14th. Nord/LB restated a neutral rating on shares of Sanofi in a research note on Wednesday, December 27th. Barclays lowered Sanofi from an equal weight rating to an underweight rating in a research note on Tuesday, January 23rd. Morgan Stanley lowered Sanofi from an overweight rating to an underweight rating in a research note on Friday, December 1st. Finally, Cowen set a $48.00 price objective on Sanofi and gave the stock a hold rating in a research note on Monday, December 18th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and two have issued a buy rating to the company. Sanofi currently has a consensus rating of Hold and an average price target of $49.33.
Shares of Sanofi (NYSE:SNY) opened at $40.65 on Monday. The company has a quick ratio of 1.26, a current ratio of 1.70 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $101,843.71, a price-to-earnings ratio of 12.95, a PEG ratio of 2.15 and a beta of 0.92. Sanofi has a 12 month low of $38.14 and a 12 month high of $50.65.
The firm also recently declared an annual dividend, which will be paid on Monday, June 4th. Shareholders of record on Thursday, May 10th will be paid a $1.8609 dividend. This represents a yield of 4.72%. The ex-dividend date of this dividend is Wednesday, May 9th. This is a positive change from Sanofi’s previous annual dividend of $1.58. Sanofi’s dividend payout ratio is presently 30.14%.
Hedge funds have recently modified their holdings of the business. STA Wealth Management LLC purchased a new stake in Sanofi in the 4th quarter worth $58,996,000. Bank of Nova Scotia Trust Co. purchased a new stake in Sanofi in the 3rd quarter worth $125,000. We Are One Seven LLC purchased a new stake in Sanofi in the 4th quarter worth $160,000. Mraz Amerine & Associates Inc. purchased a new stake in Sanofi in the 3rd quarter worth $204,000. Finally, Bronfman E.L. Rothschild L.P. increased its stake in Sanofi by 46.0% in the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 4,325 shares of the company’s stock worth $186,000 after buying an additional 1,362 shares in the last quarter. Institutional investors and hedge funds own 8.94% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Sanofi’s (SNY) “Buy” Rating Reiterated at Deutsche Bank” was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3259266/sanofis-sny-buy-rating-reiterated-at-deutsche-bank.html.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.